BVF Inc’s Spyre Therapeutics SYRE Stock Holding History

BVF Inc’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-687,080	Closed	-$14.8M	–	70
2023 Q4	$14.8M	Buy	+687,080	New	+$9.47M	0.37%	42

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc's SYRE Position: Q1 2024 in Review

BVF Inc sold out of Spyre Therapeutics (SYRE) in Q1 2024, closing a stake of 687,080 shares — an estimated $14.8M sold.

BVF Inc first reported a position in SYRE in Q4 2023 and held it in 1 quarter. The position peaked at $14.8M in Q4 2023. 103 funds tracked by Wall St. Rank hold SYRE as of Q1 2024.

BVF Inc reported no remaining Spyre Therapeutics position as of Q1 2024 after selling out during the quarter.
BVF Inc sold 687,080 Spyre Therapeutics shares in Q1 2024, an estimated $14.8M.
BVF Inc first reported a position in Spyre Therapeutics in Q4 2023 and held it in 1 quarter.
BVF Inc's Spyre Therapeutics position peaked at $14.8M in Q4 2023.
103 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2024.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.